Bristol-Myers Squibb Co (MIL:1BMY) Research & Development: €8,891 Mil (TTM As of Mar. 2026)


MIL:1BMY Bristol-Myers Squibb Co MIL:1BMY
49 GF Score
Price €50.56
GF Value €48.51
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Research & Development?

Bristol-Myers Squibb Co MIL:1BMY +3.14% 49 Research & Development is €8,891 Mil as of Mar. 2026. GuruFocus rates MIL:1BMY with a GF Score™ of 49/100 and a GF Value™ of €48.51 (Fairly Valued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Bristol-Myers Squibb Co's Research & Development for the three months ended in Mar. 2026 was €2,291 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €8,891 Mil.

Bristol-Myers Squibb Co  (MIL:1BMY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bristol-Myers Squibb Co Research & Development Related Terms

Bristol-Myers Squibb Co Research & Development Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Research & Development Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,022.58 8,976.50 8,527.18 10,656.85 8,498.15

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,087.73 2,236.86 2,153.86 2,208.44 2,291.39
MIL:1BMY
49GF Score
Bristol-Myers Squibb Co MIL:1BMY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €8,891 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €8,891 Mil mean?
Bristol-Myers Squibb Co (MIL:1BMY) has a Research & Development of €8,891 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Research & Development too high?
Bristol-Myers Squibb Co's current Research & Development is €8,891 Mil. Overall, Bristol-Myers Squibb Co has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Research & Development compare to PFE and GILD?
Bristol-Myers Squibb Co's Research & Development of €8,891 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Research & Development is €8,891 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (MIL:1BMY) is currently considered Fairly Valued. The stock's GF Value™ is €48.51, compared to a current price of €50.56 — trading 4.2% above its estimated fair value. The current Research & Development is €8,891 Mil. Bristol-Myers Squibb Co's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Bristol-Myers Squibb Co (MIL:1BMY), the current Research & Development is €8,891 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (MIL:1BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of €50.56 is trading 4.2% above its estimated GF Value™ of €48.51. GuruFocus considers Bristol-Myers Squibb Co to be Fairly Valued.

Key valuation signals for MIL:1BMY:

  • Research & Development: €8,891 Mil
  • GF Value™: €48.51 vs. price of €50.56 (4.2% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the MIL:1BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
49GF Score

Get the complete analysis for MIL:1BMY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€50.56
Price
€48.51
GF Value